Revenues from the company’s molecular diagnostics business grew 6 percent, driven by continued strength in sales of women's health products.
The automated device was able to detect pathogens from clinical samples and can be built from a 3D printer retailing at $750 or less.
Sequences from Chlamydia trachomatis strains in northern Australia suggest trachoma infections in the eye may be caused by small changes to urogenital strains.
The firm has improved design of the system for low-resource settings and validated it on clinical chlamydia samples and extracted HIV, Ebola, and dengue samples.
The revenue increase was driven by growth in Meridian's Diagnostics segment and particularly sales of its Illumigene product line.
The CE mark is for two assays covering chlamydia, gonorrhea, and trichomonas, and which run on the BD Max system.
Meridian received the CE mark for two new Illumigene molecular diagnostic tests for Chlamydia trachomatis and Neisseria gonorrhoeae.
According to the firm's CEO, the delay in launching the io system is due to a decision to automate parts of its platform, resulting in increased multiplexing.
The waiver opens up a significant new opportunity for Alere within the physician office market, according to a company executive.
Trends included expanding test menus and a possible tipping point for point-of-care.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.